ORNIPEST LYOPHILISATE

Indications

• Mycobacterium avium complex infection
• Pulmonary disease due to Mycobacterium avium
• Disseminated Mycobacterium avium infection in immunocompromised patients
• Lymphadenitis caused by Mycobacterium avium

Dosage

Children: Refer to the latest prescribing guidelines for specific dosing regimens, as they may vary based on the drug chosen and the age and weight of the child.

Adults: Refer to the latest prescribing guidelines for specific dosing regimens, as they may vary based on the drug chosen and the severity of infection.

Mechanism of action

The antibiotics used to treat Mycobacterium avium complex, such as azithromycin, clarithromycin, and rifabutin, work by inhibiting bacterial protein synthesis or disrupting cell wall synthesis. Specifically, macrolides like azithromycin and clarithromycin bind to the 50S ribosomal subunit of bacteria, blocking translocation and ultimately inhibiting protein synthesis.

Pharmacodynamics

Azithromycin and clarithromycin exhibit bacteriostatic activity against Mycobacterium avium by preventing the growth and reproduction of the bacteria. The drug concentrations required for effectiveness are typically achieved in macrophages, where the bacteria reside, allowing for effective treatment of intracellular infections. Their ability to penetrate tissues and reach high intracellular concentrations enhances their efficacy against these pathogens.

Pharmacokinetics

The pharmacokinetics of azithromycin and clarithromycin involve oral absorption with high bioavailability. They are widely distributed in body tissues, including the lungs and macrophages. Azithromycin has a long half-life, allowing for once-daily dosing. Both drugs are metabolized in the liver and have some renal excretion. The elimination half-life allows for effective dosing schedules that improve patient adherence.

Pregnancy

Avium has not been adequately studied in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether Avium is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Measles
• Mumps
• Respiratory syncytial virus infection
• Parainfluenza virus infection

Dosage

Children: Specific dosing information is not applicable as paramyxovirus infections are typically managed through supportive care and prevention strategies such as vaccination.

Adults: Specific dosing information is not applicable as paramyxovirus infections are typically managed through supportive care and prevention strategies such as vaccination.

Mechanism of action

Paramyxoviruses enter host cells through receptor-mediated endocytosis. The viral fusion protein facilitates the fusion of the viral envelope with the host cell membrane, allowing the viral RNA to enter the cytoplasm. Once inside, the viral RNA is transcribed and replicated, leading to the production of viral proteins and new virions. The immune response to paramyxovirus infections can contribute to the pathology observed, including inflammation and tissue damage.

Pharmacodynamics

The clinical manifestations of paramyxovirus infections are often due to the host immune response rather than direct viral damage. Symptoms can include fever, cough, rash, and in some cases, severe respiratory distress. The severity of disease can vary based on the specific virus, the age and immune status of the host, and pre-existing health conditions. Vaccination plays a crucial role in preventing paramyxovirus infections and their associated complications.

Pharmacokinetics

As paramyxoviruses are not treated with traditional antiviral medications, pharmacokinetic data on these viruses is not applicable. However, the duration of viral shedding can vary among different paramyxoviruses and is influenced by the host's immune response. The incubation period for infections can range from several days to weeks, depending on the specific virus.

Adverse effects

• Fever
• Cough
• Rash
• Conjunctivitis
• Encephalitis
• Parotitis
• Pneumonia

Precautions

• Use caution in immunocompromised individuals
• Monitor for respiratory complications
• Ensure patients are up to date with vaccinations

Pregnancy

The safety of this virus during pregnancy has not been fully established; consult a healthcare provider for guidance.

Breast-feeding

It is unknown whether paramyxovirus is excreted in human milk; caution is advised.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Bubonic plague
• Septicemic plague
• Pneumonic plague

Dosage

Children: Refer to specific clinical guidelines for appropriate pediatric dosing based on age and weight.

Adults: Refer to specific clinical guidelines for detailed dosing regimens depending on the form of plague and severity of the infection.

Mechanism of action

Yersinia pestis, the causative agent of pseudopestis, employs various virulence factors to invade host tissues and evade the immune response. The bacterium utilizes a type III secretion system to inject virulence proteins directly into host cells, which disrupts cellular processes and facilitates bacterial survival and replication within phagocytic cells. This leads to systemic infection and the characteristic symptoms of plague.

Pharmacodynamics

The pharmacodynamics of treatments for pseudopestis largely involves the inhibition of bacterial growth and replication. Antibiotics such as streptomycin and doxycycline are commonly used, exerting their effects by disrupting protein synthesis or cell wall synthesis in susceptible bacteria. The rapid initiation of antibiotic treatment is critical to improve outcomes in infected individuals.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat pseudopestis varies by drug. For instance, streptomycin is administered via intramuscular injection, with peak serum concentrations achieved within 1-2 hours. It is primarily excreted unchanged in the urine. Doxycycline, taken orally, is well absorbed with bioavailability around 90%, and has a half-life of about 18-22 hours. It is distributed widely in body tissues and fluids, penetrates well into the central nervous system, and is excreted primarily through the liver and kidneys.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether pseudopestis is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.